Related Experiment Video
Updated: Aug 16, 2026
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Pathogenic antibody removal using magnetically stabilized fluidized bed
Mehmet Odabaşi1, Nihal Ozkayar, Serpil Ozkara
1Department of Chemistry, Biochemistry Division, Hacettepe University, Ankara, Turkey.
Abstract:
Magnetic poly(2-hydroxyethyl methacrylate) (mPHEMA) beads were used in the removal of anti-dsDNA antibodies from systemic lupus erythematosus (SLE) patient plasma in a magnetically stabilized fluidized bed. mPHEMA beads, in the size range of 80-120 microm, were produced by suspension technique. Then, DNA was immobilized onto mPHEMA beads by carbodiimide activation. Magnetic beads were contacted with blood in in vitro systems. Loss of blood cells and clotting times were followed. mPHEMA beads were characterized by scanning electron microscopy (SEM). Important results obtained in this study are as follows: the mPHEMA beads have a spherical shape and porous structure. Loss of cells in the blood contacting with mPHEMA/DNA was negligible. The anti-dsDNA adsorption capacity decreased significantly with the increase of the flow-rate. With increasing anti-dsDNA antibody concentration, the amount of antibody adsorbed per unit mass increased, then reached saturation. Maximum anti-dsDNA antibody adsorption capacity was found to be 97.8 mg/g. Pathogenic antibody molecules could be repeatedly adsorbed and desorbed with these magnetic beads without noticeable loss in their antibody adsorption capacity. Because of the good blood-compatibility, mPHEMA is hopeful for the treatment of SLE by magnetically stabilized fluidized bed systems in the future.
Insights
Magnetic poly(2-hydroxyethyl methacrylate) (mPHEMA) beads effectively remove anti-double-stranded DNA (dsDNA) antibodies from systemic lupus erythematosus (SLE) patient plasma. These reusable beads show promise for future SLE treatments using magnetically stabilized fluidized beds.
Area of Science:
- Biomaterials Science
- Immunology
- Medical Device Engineering
Background:
- Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of anti-double-stranded DNA (anti-dsDNA) antibodies.
- Effective removal of these pathogenic antibodies from patient plasma is crucial for managing SLE.
- Magnetic beads offer potential for targeted and efficient extracorporeal blood treatment.
Purpose of the Study:
- To develop and evaluate magnetic poly(2-hydroxyethyl methacrylate) (mPHEMA) beads for the removal of anti-dsDNA antibodies from SLE patient plasma.
- To assess the performance of these beads in a magnetically stabilized fluidized bed system.
- To investigate the biocompatibility and reusability of the mPHEMA beads for potential therapeutic applications.
Main Methods:
- mPHEMA beads (80-120 microm) were synthesized using a suspension technique.
- DNA was immobilized onto mPHEMA beads via carbodiimide activation.
- In vitro studies involved contacting magnetic beads with patient plasma in a magnetically stabilized fluidized bed, monitoring cell loss, clotting times, and antibody adsorption.
Main Results:
- Characterization confirmed mPHEMA beads possess a spherical and porous structure.
- Negligible loss of blood cells and normal clotting times were observed upon contact with mPHEMA/DNA beads.
- Anti-dsDNA antibody adsorption capacity decreased with increased flow rate but increased with antibody concentration, reaching saturation.
- Maximum adsorption capacity was 97.8 mg/g, with efficient and repeatable adsorption/desorption cycles.
Conclusions:
- mPHEMA/DNA magnetic beads demonstrate excellent biocompatibility and high capacity for removing anti-dsDNA antibodies from SLE patient plasma.
- The magnetically stabilized fluidized bed system using mPHEMA beads is a promising approach for SLE treatment.
- These reusable magnetic beads offer a potential therapeutic strategy for managing SLE by reducing pathogenic autoantibodies.
